GlassScriptPhysician profile
Ali Naboush
NPI 1134410277
$4,197.76
in general payments reported to CMS, 2019-2025
44 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $872 · 2022: $2,737 · 2023: $411 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.13 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $645.06 | 2021-2023 | |
| Lilly USA, LLC | $330.52 | 2021-2023 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $311.89 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $257.08 | 2022 | |
| Daiichi Sankyo INC. | $211.94 | 2021-2023 | Enhertu |
| Seagen INC. | $202.95 | 2021-2022 | |
| Janssen Biotech, INC. | $195.84 | 2021-2023 | Erleada |
| Eisai INC. | $149.07 | 2021-2022 | |
| Genzyme Corporation | $130.08 | 2021-2025 | |
| Pfizer INC. | $127.72 | 2022-2023 | |
| Kite Pharma, INC. | $117.78 | 2021-2022 | |
| Puma Biotechnology, INC. | $103.39 | 2021-2022 | |
| Emd Serono, INC. | $103.33 | 2021-2023 | Bavencio |
| E.R. Squibb & Sons, L.L.C. | $96.15 | 2021-2022 | |
| Organon LLC | $94.96 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Naboush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.